TriangleDISEASE & TREATMENT SETTING
recurrent Small Intestine Cancer
Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.
Exact scope
Treatment of Recurrent Small Intestine Cancer
Broader topic: Small Intestine Cancer
- Source population
- Not part of this definition
- Disease extent
- recurrent
- Treatment line
- Not part of this definition
- Stage
- Not part of this definition
- Resectability
- Not part of this definition
Biomarkers, prior therapy and derivation
- molecular
- prior therapy
- class
- prior therapy
- status
- stated
- derivation status
- source-attested
- derivation note
- Scoped from an NCI treatment-summary heading. NCI PDQ is an evidence summary, not a practice guideline, and only the dimensions the heading states are part of this definition.
- source wording
- Treatment of Recurrent Small Intestine Cancer
Study evidence for this setting
Clofarabine in Treating Patients With T-Cell or Natural Killer-Cell Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment
Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer
Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas
Pembrolizumab in Treating Patients With Small Bowel Adenocarcinoma That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery
Source relationships and population-mapping limitations
- bindings
- mappings
Download this complete draft source relationship record →
Preserved source evidence · Not medical advice